Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

The influence of genetic variation on late toxicities in childhood cancer survivors: A review.

Clemens E, van der Kooi ALF, Broer L, van Dulmen-den Broeder E, Visscher H, Kremer L, Tissing W, Loonen J, Ronckers CM, Pluijm SMF, Neggers SJCMM, Zolk O, Langer T, Zehnhoff-Dinnesen AA, Wilson CL, Hudson MM, Carleton B, Laven JSE, Uitterlinden AG, van den Heuvel-Eibrink MM.

Crit Rev Oncol Hematol. 2018 Jun;126:154-167. doi: 10.1016/j.critrevonc.2018.04.001. Epub 2018 Apr 12. Review.

PMID:
29759558
2.

A Triassic-Jurassic window into the evolution of Lepidoptera.

van Eldijk TJB, Wappler T, Strother PK, van der Weijst CMH, Rajaei H, Visscher H, van de Schootbrugge B.

Sci Adv. 2018 Jan 10;4(1):e1701568. doi: 10.1126/sciadv.1701568. eCollection 2018 Jan.

3.

An initial health economic evaluation of pharmacogenomic testing in patients treated for childhood cancer with anthracyclines.

Dionne F, Aminkeng F, Bhavsar AP, Groeneweg G, Smith A, Visscher H, Rassekh SR, Ross C, Carleton B.

Pediatr Blood Cancer. 2018 Mar;65(3). doi: 10.1002/pbc.26887. Epub 2017 Dec 22.

PMID:
29271558
4.

A coding variant in RARG confers susceptibility to anthracycline-induced cardiotoxicity in childhood cancer.

Aminkeng F, Bhavsar AP, Visscher H, Rassekh SR, Li Y, Lee JW, Brunham LR, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Amstutz U, Rieder MJ, Bernstein D, Carleton BC, Hayden MR, Ross CJ; Canadian Pharmacogenomics Network for Drug Safety Consortium.

Nat Genet. 2015 Sep;47(9):1079-84. doi: 10.1038/ng.3374. Epub 2015 Aug 3.

5.

Genetic variants in SLC22A17 and SLC22A7 are associated with anthracycline-induced cardiotoxicity in children.

Visscher H, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR, Ross CJ; CPNDS consortium.

Pharmacogenomics. 2015;16(10):1065-76. doi: 10.2217/pgs.15.61. Epub 2015 Jul 31.

PMID:
26230641
6.

Genetic markers of cisplatin-induced hearing loss in children.

Carleton BC, Ross CJ, Pussegoda K, Bhavsar AP, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Sep;96(3):296-8. doi: 10.1038/clpt.2014.92.

PMID:
25141953
7.

Response to "evaluation of pharmacogenetic markers to predict the risk of Cisplatin-induced ototoxicity".

Carleton BC, Ross CJ, Bhavsar AP, Lee JW, Visscher H, Rassekh SR, Hayden MR.

Clin Pharmacol Ther. 2014 Aug;96(2):158. doi: 10.1038/clpt.2014.90. Epub 2014 Apr 22. No abstract available.

PMID:
24755913
8.

Role of TPMT and COMT genetic variation in cisplatin-induced ototoxicity.

Carleton BC, Ross CJ, Bhavsar AP, Amstutz U, Pussegoda K, Visscher H, Lee JW, Brooks B, Rassekh SR, Dubé MP, Hayden MR.

Clin Pharmacol Ther. 2014 Mar;95(3):253. doi: 10.1038/clpt.2013.219. Epub 2013 Nov 5. No abstract available.

PMID:
24193170
9.

Replication of TPMT and ABCC3 genetic variants highly associated with cisplatin-induced hearing loss in children.

Pussegoda K, Ross CJ, Visscher H, Yazdanpanah M, Brooks B, Rassekh SR, Zada YF, Dubé MP, Carleton BC, Hayden MR; CPNDS Consortium.

Clin Pharmacol Ther. 2013 Aug;94(2):243-51. doi: 10.1038/clpt.2013.80. Epub 2013 Apr 10.

10.

Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Rogers PC, Rieder MJ, Carleton BC, Hayden MR; CPNDS Consortium.

Pediatr Blood Cancer. 2013 Aug;60(8):1375-81. doi: 10.1002/pbc.24505. Epub 2013 Feb 25.

PMID:
23441093
11.

Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children.

Visscher H, Ross CJ, Rassekh SR, Barhdadi A, Dubé MP, Al-Saloos H, Sandor GS, Caron HN, van Dalen EC, Kremer LC, van der Pal HJ, Brown AM, Rogers PC, Phillips MS, Rieder MJ, Carleton BC, Hayden MR; Canadian Pharmacogenomics Network for Drug Safety Consortium.

J Clin Oncol. 2012 May 1;30(13):1422-8. doi: 10.1200/JCO.2010.34.3467. Epub 2011 Sep 6.

PMID:
21900104
12.
13.

Pharmacogenomics of serious adverse drug reactions in pediatric oncology.

Ross CJ, Visscher H, Rassekh SR, Castro-Pastrana LI, Shereck E, Carleton B, Hayden MR.

J Popul Ther Clin Pharmacol. 2011;18:e134-51. Epub 2011 Mar 21. Review.

PMID:
21467604
14.

Pharmacogenomics of cardiovascular drugs and adverse effects in pediatrics.

Visscher H, Amstutz U, Sistonen J, Ross CJ, Hayden MR, Carleton BC.

J Cardiovasc Pharmacol. 2011 Sep;58(3):228-39. doi: 10.1097/FJC.0b013e3182163b82. Review.

PMID:
21386709
15.

HTT haplotypes contribute to differences in Huntington disease prevalence between Europe and East Asia.

Warby SC, Visscher H, Collins JA, Doty CN, Carter C, Butland SL, Hayden AR, Kanazawa I, Ross CJ, Hayden MR.

Eur J Hum Genet. 2011 May;19(5):561-6. doi: 10.1038/ejhg.2010.229. Epub 2011 Jan 19.

16.

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin.

Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK, Visscher H, Jukema JW, Stalenhoef AF, Ross CJ, Carleton BC, Kastelein JJ, Hayden MR.

Pharmacogenomics J. 2012 Jun;12(3):233-7. doi: 10.1038/tpj.2010.92. Epub 2011 Jan 18.

PMID:
21243006
17.

Pharmacogenomics and active surveillance for serious adverse drug reactions in children.

Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC.

Pharmacogenomics. 2010 Sep;11(9):1269-85. doi: 10.2217/pgs.10.111. Review.

PMID:
20860467
18.

The Canadian Pharmacogenomics Network for Drug Safety: a model for safety pharmacology.

Ross CJ, Visscher H, Sistonen J, Brunham LR, Pussegoda K, Loo TT, Rieder MJ, Koren G, Carleton BC, Hayden MR; CPNDS Consortium.

Thyroid. 2010 Jul;20(7):681-7. doi: 10.1089/thy.2010.1642. Review.

PMID:
20578893
19.

Response to Falush: a role for cis-element polymorphisms in HD.

Warby SC, Visscher H, Butland S, Pearson CE, Hayden MR.

Am J Hum Genet. 2009 Dec;85(6):942-5. doi: 10.1016/j.ajhg.2009.11.006. No abstract available.

20.

Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy.

Ross CJ, Katzov-Eckert H, Dubé MP, Brooks B, Rassekh SR, Barhdadi A, Feroz-Zada Y, Visscher H, Brown AM, Rieder MJ, Rogers PC, Phillips MS, Carleton BC, Hayden MR; CPNDS Consortium.

Nat Genet. 2009 Dec;41(12):1345-9. doi: 10.1038/ng.478. Epub 2009 Nov 8. Erratum in: Nat Genet. 2013 May;45(5):578.

PMID:
19898482
21.

Application of principal component analysis to pharmacogenomic studies in Canada.

Visscher H, Ross CJ, Dubé MP, Brown AM, Phillips MS, Carleton BC, Hayden MR.

Pharmacogenomics J. 2009 Dec;9(6):362-72. doi: 10.1038/tpj.2009.36. Epub 2009 Aug 4.

PMID:
19652663
22.

CAG expansion in the Huntington disease gene is associated with a specific and targetable predisposing haplogroup.

Warby SC, Montpetit A, Hayden AR, Carroll JB, Butland SL, Visscher H, Collins JA, Semaka A, Hudson TJ, Hayden MR.

Am J Hum Genet. 2009 Mar;84(3):351-66. doi: 10.1016/j.ajhg.2009.02.003. Epub 2009 Feb 26.

23.

A role for atmospheric CO2 in preindustrial climate forcing.

van Hoof TB, Wagner-Cremer F, Kürschner WM, Visscher H.

Proc Natl Acad Sci U S A. 2008 Oct 14;105(41):15815-8. doi: 10.1073/pnas.0807624105. Epub 2008 Oct 6.

24.

Human herpes virus 6 plasma DNA positivity after hematopoietic stem cell transplantation in children: an important risk factor for clinical outcome.

de Pagter PJ, Schuurman R, Visscher H, de Vos M, Bierings M, van Loon AM, Uiterwaal CS, van Baarle D, Sanders EA, Boelens J.

Biol Blood Marrow Transplant. 2008 Jul;14(7):831-9. doi: 10.1016/j.bbmt.2008.04.016.

25.

Specific mutations in ABCA1 have discrete effects on ABCA1 function and lipid phenotypes both in vivo and in vitro.

Singaraja RR, Visscher H, James ER, Chroni A, Coutinho JM, Brunham LR, Kang MH, Zannis VI, Chimini G, Hayden MR.

Circ Res. 2006 Aug 18;99(4):389-97. Epub 2006 Jul 27.

26.

Mid- to late-Holocene El Nino-Southern Oscillation dynamics reflected in the subtropical terrestrial realm.

Donders TH, Wagner F, Dilcher DL, Visscher H.

Proc Natl Acad Sci U S A. 2005 Aug 2;102(31):10904-8. Epub 2005 Jul 25.

27.

Alternate transcripts expressed in response to diet reflect tissue-specific regulation of ABCA1.

Singaraja RR, James ER, Crim J, Visscher H, Chatterjee A, Hayden MR.

J Lipid Res. 2005 Oct;46(10):2061-71. Epub 2005 Jul 16.

28.

Stomatal frequency responses in hardwood-swamp vegetation from Florida during a 60-year continuous CO2 increase.

Wagner F, Dilcher DL, Visscher H.

Am J Bot. 2005 Apr;92(4):690-5. doi: 10.3732/ajb.92.4.690.

29.

Changes in stomatal frequency and size during elongation of Tsuga heterophylla needles.

Kouwenberg LL, Kürschner WM, Visscher H.

Ann Bot. 2004 Oct;94(4):561-9. Epub 2004 Aug 20.

30.

Environmental mutagenesis during the end-Permian ecological crisis.

Visscher H, Looy CV, Collinson ME, Brinkhuis H, van Konijnenburg-van Cittert JH, Kürschner WM, Sephton MA.

Proc Natl Acad Sci U S A. 2004 Aug 31;101(35):12952-6. Epub 2004 Jul 28.

31.

Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene.

Singaraja RR, Brunham LR, Visscher H, Kastelein JJ, Hayden MR.

Arterioscler Thromb Vasc Biol. 2003 Aug 1;23(8):1322-32. Epub 2003 May 22. Review.

32.

Alterations of plasma lipids in mice via adenoviral-mediated hepatic overexpression of human ABCA1.

Wellington CL, Brunham LR, Zhou S, Singaraja RR, Visscher H, Gelfer A, Ross C, James E, Liu G, Huber MT, Yang YZ, Parks RJ, Groen A, Fruchart-Najib J, Hayden MR.

J Lipid Res. 2003 Aug;44(8):1470-80. Epub 2003 May 1.

33.

Stomatal frequency adjustment of four conifer species to historical changes in atmospheric CO2.

Kouwenberg LL, McElwain JC, Kürschner WM, Wagner F, Beerling DJ, Mayle FE, Visscher H.

Am J Bot. 2003 Apr;90(4):610-9. doi: 10.3732/ajb.90.4.610.

34.

Rapid atmospheric CO2 changes associated with the 8,200-years-B.P. cooling event.

Wagner F, Aaby B, Visscher H.

Proc Natl Acad Sci U S A. 2002 Sep 17;99(19):12011-4. Epub 2002 Aug 29.

35.

Life in the end-Permian dead zone.

Looy CV, Twitchett RJ, Dilcher DL, Van Konijnenburg-Van Cittert JH, Visscher H.

Proc Natl Acad Sci U S A. 2001 Jul 3;98(14):7879-83. Epub 2001 Jun 26.

36.

The delayed resurgence of equatorial forests after the permian-triassic ecologic crisis.

Looy CV, Brugman WA, Dilcher DL, Visscher H.

Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):13857-62.

37.

Century-scale shifts in early holocene atmospheric CO2 concentration

Wagner F, Bohncke SJ, Dilcher DL, Kurschner WM, van Geel B, Visscher H.

Science. 1999 Jun 18;284(5422):1971-3.

38.
39.

A natural experiment on plant acclimation: lifetime stomatal frequency response of an individual tree to annual atmospheric CO2 increase.

Wagner F, Below R, Klerk PD, Dilcher DL, Joosten H, Kürschner WM, Visscher H.

Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11705-8.

40.

The terminal Paleozoic fungal event: evidence of terrestrial ecosystem destabilization and collapse.

Visscher H, Brinkhuis H, Dilcher DL, Elsik WC, Eshet Y, Looy CV, Rampino MR, Traverse A.

Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2155-8.

41.

The role of the obstetrician/gynecologist in primary health care.

Visscher HC.

Clin Obstet Gynecol. 1995 Mar;38(1):206-12. Review. No abstract available.

PMID:
7796549
42.

Randomised crossover comparison of adrenal suppressive effects of dermal creams containing glucocorticosteroids.

Visscher HW, Ebels JT, Roders GA, Jonkman JG.

Eur J Clin Pharmacol. 1995;48(2):123-5.

PMID:
7589025
43.

Assessment of the resident in-training examination in obstetrics and gynecology.

Cox SM, Herbert WN, Grosswald SJ, Carpentieri AM, Visscher HC, Laube DW.

Obstet Gynecol. 1994 Dec;84(6):1051-4.

PMID:
7970465
44.

Lack of pharmacokinetic interaction between vinpocetine and oxazepam.

Storm G, Oosterhuis B, Sollie FA, Visscher HW, Sommer W, Beitinger H, Jonkman JH.

Br J Clin Pharmacol. 1994 Aug;38(2):143-6.

45.

A comparative study of the steady-state pharmacokinetics of immediate-release and controlled-release diltiazem tablets.

Leeuwenkamp OR, Visscher HW, Mensink CK, Jonkman JH.

Eur J Clin Pharmacol. 1994;46(3):243-7.

PMID:
8070505
46.

Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects.

Huang ML, Van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen AA, Zylicz Z, Visscher HW, Jonkman JH.

Clin Pharmacol Ther. 1993 Sep;54(3):257-68.

PMID:
7690693
47.

Paleoatmospheric signatures in neogene fossil leaves.

Van Der Burgh J, Visscher H, Dilcher DL, Kürschner WM.

Science. 1993 Jun 18;260(5115):1788-90.

PMID:
17793657
48.

Opinions and approaches to continuing education among obstetrician/gynecologists.

Herbert WN, Moos MK, Frierson HT Jr, Davis WA, Grosswald SJ, Visscher HC.

Obstet Gynecol. 1989 Jul;74(1):125-30.

PMID:
2733928
49.

Information management needs of the obstetrician-gynecologist--a survey.

Jelovsek FR, Rittwage J, Pearse WH, Visscher HC.

Obstet Gynecol. 1989 Mar;73(3 Pt 1):395-9.

PMID:
2915863
50.

Supplemental Content

Loading ...
Support Center